ReviewFrontiers in aging neuroscience2025
Structural and microstructural changes in white and gray matter across the Alzheimer's disease continuum.
Review in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- Alzheimer's Disease Selectively Perturbs Age-Sensitive Brain Radiomic Features Across the Disease Continuum.bioRxiv : the preprint server for biology · 2026Article
- Frontal Lobe and Subregional Volumetric Alterations Across Alzheimer's Disease, Amnestic Mild Cognitive Impairment, and Vascular Dementia: An MRI Volumetry Study.Brain sciences · 2026Article
- MRI In Vivo Detection of Amyloid-β Protein Deposition in Different Brain Regions of Patients with AD and MCI.Brain topography · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive brain atrophy, with pathological progression accompanied by significant structural alterations in both gray matter (GM) and white matter (WM). This review summarizes the neuroimaging features and clinical implications of brain volumetric changes across distinct the clinical phases of the AD continuum [preclinical phase, subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia phase]. Our analysis reveals a key conceptual advance: the spatiotemporal pattern of WM volume loss is not merely a consequence of GM degeneration but an active and complementary contributor to clinical decline. We identify specific, underappreciated WM tracts whose atrophy rates offer unique prognostic value beyond hippocampal volume. The primary contribution of this work is a unified model of AD neuroanatomy, which challenges the isolated view of GM and WM pathology. This refined understanding is critical for developing the next generation of biomarkers and underscores the imperative to leverage artificial intelligence for analyzing these complex, multi-tissue interactions. Future research should further integrate artificial intelligence and multi-omics data to refine personalized predictive models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.